An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers

An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers

ABSTRACT Background and Aims Sensitivity to immune checkpoint inhibitor (ICI) therapy depends in part on the genetic and epigenetic makeup of cancer cells, and CD8 T‐lymphocytes that mediate immune responses. Epigenetics are heritable reversible changes in gene expression that occur without any chan...

Full description

Saved in:
Bibliographic Details
Main Authors: Vinod K. Ramani, Srimonta Gayen, Radheshyam Naik
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Health Science Reports
Subjects:
azacitidine
DNA hypomethylation
head and neck cancer
immunotherapy
pembrolizumab
Online Access:https://doi.org/10.1002/hsr2.70233
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items